1. de Souza, HS, Fiocchi, C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol 2016; 13: 13–27.
Google Scholar | Crossref | Medline | ISI2. Torres, J, Mehandru, S, Colombel, J-F, et al. Crohn’s disease. Lancet 2017; 389: 1741–1755.
Google Scholar | Crossref | Medline3. Ungaro, R, Mehandru, S, Allen, PB, et al. Ulcerative colitis. Lancet 2017; 389: 1756–1770.
Google Scholar | Crossref | Medline4. Abraham, C, Cho, JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066–2078.
Google Scholar | Crossref | Medline | ISI5. Ng, SC, Shi, HY, Hamidi, N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390: 2769–2778.
Google Scholar | Crossref | Medline6. Kaplan, GG, Ng, SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017; 152: 313–321.e2.
Google Scholar | Crossref7. Kaplan, GG . The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol 2015; 12: 720–727.
Google Scholar | Crossref | Medline8. Sands, BE . Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology 2015; 149: 1275–1285.e2.
Google Scholar | Crossref9. Storr, M, Vogel, HJ, Schicho, R. Metabolomics: is it useful for inflammatory bowel diseases? Curr Opin Gastroenterol 2013; 29: 378–383.
Google Scholar | Crossref | Medline10. Wishart, DS . Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev 2019; 99: 1819–1875.
Google Scholar | Crossref | Medline11. Bauset, C, Gisbert-Ferrandiz, L, Cosin-Roger, J. Metabolomics as a promising resource identifying potential biomarkers for inflammatory bowel disease. J Clin Med 2021; 10: 622.
Google Scholar | Crossref | Medline12. Gallagher, K, Catesson, A, Griffin, JL, et al. Metabolomic analysis in inflammatory bowel disease: a systematic review. J Crohns Colitis 2021; 15: 813–826.
Google Scholar | Crossref | Medline13. Lin, HM, Helsby, NA, Rowan, DD, et al. Using metabolomic analysis to understand inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 1021–1029.
Google Scholar | Crossref | Medline14. Patti, GJ, Yanes, O, Siuzdak, G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012; 13: 263–269.
Google Scholar | Crossref | Medline | ISI15. Dudley, E, Yousef, M, Wang, Y, et al. Targeted metabolomics and mass spectrometry. Adv Protein Chem Struct Biol 2010; 80: 45–83.
Google Scholar | Crossref | Medline16. Dunn, WB, Bailey, NJC, Johnson, HE. Measuring the metabolome: current analytical technologies. Analyst 2005; 130: 606–625.
Google Scholar | Crossref | Medline | ISI17. Beckonert, O, Keun, HC, Ebbels, TMD, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2007; 2: 2692–2703.
Google Scholar | Crossref | Medline | ISI18. Dettmer, K, Aronov, PA, Hammock, BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev 2007; 26: 51–78.
Google Scholar | Crossref | Medline | ISI19. Pan, Z, Raftery, D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem 2007; 387: 525–527.
Google Scholar | Crossref | Medline20. Lindon, JC, Nicholson, JK. Analytical technologies for metabonomics and metabolomics, and multi-omic information recovery. TrAC: Trend Anal Chem 2008; 27: 194–204.
Google Scholar | Crossref21. Harbord, M, Eliakim, R, Bettenworth, D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2017; 11: 769–784.
Google Scholar | Crossref | Medline22. Gomollón, F, Dignass, A, Annese, V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 2017; 11: 3–25.
Google Scholar | Crossref | Medline23. Turner, D, Ricciuto, A, Lewis, A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160: 1570–1583.
Google Scholar | Crossref | Medline24. Keshteli, AH, Tso, R, Dieleman, LA, et al. A distinctive urinary metabolomic fingerprint is linked with endoscopic postoperative disease recurrence in Crohn’s disease patients. Inflamm Bowel Dis 2018; 24: 861–870.
Google Scholar | Crossref | Medline25. Kolho, KL, Pessia, A, Jaakkola, T, et al. Faecal and serum metabolomics in paediatric inflammatory bowel disease. J Crohns Colitis 2017; 11: 321–334.
Google Scholar | Medline26. Sedghi, S, Keshavarzian, A, Klamut, M, et al. Elevated breath ethane levels in active ulcerative colitis: evidence for excessive lipid peroxidation. Am J Gastroenterol 1994; 89: 2217–2221.
Google Scholar | Medline27. Taylor, H, Serrano-Contreras, JI, McDonald, JAK, et al. Multiomic features associated with mucosal healing and inflammation in paediatric Crohn’s disease. Aliment Pharmacol Ther 2020; 52: 1491–1502.
Google Scholar | Medline28. Diab, J, Al-Mahdi, R, Gouveia-Figueira, S, et al. A quantitative analysis of colonic mucosal oxylipins and endocannabinoids in treatment-naive and deep remission ulcerative colitis patients and the potential link with cytokine gene expression. Inflamm Bowel Dis 2019; 25: 490–497.
Google Scholar | Crossref | Medline29. Diab, J, Hansen, T, Goll, R, et al. Lipidomics in ulcerative colitis reveal alteration in mucosal lipid composition associated with the disease state. Inflamm Bowel Dis 2019; 25: 1780–1787.
Google Scholar | Crossref | Medline30. Bjerrum, JT, Rantalainen, M, Wang, Y, et al. Integration of transcriptomics and metabonomics: improving diagnostics, biomarker identification and phenotyping in ulcerative colitis. Metabolomics 2014; 10: 280–290.
Google Scholar | Crossref | Medline31. Probert, F, Walsh, A, Jagielowicz, M, et al. Plasma nuclear magnetic resonance metabolomics discriminates between high and low endoscopic activity and predicts progression in a prospective cohort of patients with ulcerative colitis. J Crohns Colitis 2018; 12: 1326–1337.
Google Scholar | Crossref | Medline32. Bodelier, AG, Smolinska, A, Baranska, A, et al. Volatile organic compounds in exhaled air as novel marker for disease activity in Crohn’s disease: a metabolomic approach. Inflamm Bowel Dis 2015; 21: 1776–1785.
Google Scholar | Crossref | Medline33. Diab, J, Hansen, T, Goll, R, et al. Mucosal metabolomic profiling and pathway analysis reveal the metabolic signature of ulcerative colitis. Metabolites 2019; 9: 291.
Google Scholar | Crossref34. Di Giovanni, N, Meuwis, MA, Louis, E, et al. Untargeted serum metabolic profiling by comprehensive two-dimensional gas chromatography-high-resolution time-of-flight mass spectrometry. J Proteome Res 2020; 19: 1013–1028.
Google Scholar | Crossref | Medline35. Mosli, MH, Zou, G, Garg, SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol 2015; 110: 802–819; quiz 820.
Google Scholar | Crossref | Medline | ISI36. Gupta, A, Yu, A, Peyrin-Biroulet, L, et al. Treat to target: the role of histologic healing in inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021; 19: 1800–1813.e4.
Google Scholar | Crossref37. Ding, NS, McDonald, JAK, Perdones-Montero, A, et al. Metabonomics and the gut microbiome associated with primary response to anti-TNF therapy in Crohn’s disease. J Crohns Colitis 2020; 14: 1090–1102.
Google Scholar | Crossref | Medline38. Aden, K, Rehman, A, Waschina, S, et al. Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases. Gastroenterology 2019; 157: 1279–1292.e11.
Google Scholar | Crossref39. Nikolaus, S, Schulte, B, Al-Massad, N, et al. Increased tryptophan metabolism is associated with activity of inflammatory bowel diseases. Gastroenterology 2017; 153: 1504–1516.e2.
Google Scholar | Crossref | Medline40. Gerasimidis, K, Bertz, M, Hanske, L, et al. Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn’s disease during enteral nutrition. Inflamm Bowel Dis 2014; 20: 861–871.
Google Scholar | Crossref | Medline | ISI41. Yamamoto, M, Shanmuganathan, M, Hart, L, et al. Urinary metabolites enable differential diagnosis and therapeutic monitoring of pediatric inflammatory bowel disease. Metabolites 2021; 11: 245.
Google Scholar | Crossref | Medline42. Nusbaum, DJ, Sun, F, Ren, J, et al. Gut microbial and metabolomic profiles after fecal microbiota transplantation in pediatric ulcerative colitis patients. FEMS Microbiol Ecol 2018; 94: fiy133.
Google Scholar | Crossref | Medline43. Costello, SP, Hughes, PA, Waters, O, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 2019; 321: 156–164.
Google Scholar | Crossref | Medline44. Paramsothy, S, Nielsen, S, Kamm, MA, et al. Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis. Gastroenterology 2019; 156: 1440–1454.e2.
Google Scholar | Crossref | Medline45. Diederen, K, Li, JV, Donachie, GE, et al. Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn’s disease. Sci Rep 2020; 10: 18879.
Google Scholar | Crossref | Medline46. Li, P, Zhang, T, Xiao, Y, et al. Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn’s disease. Appl Microbiol Biotechnol 2019; 103: 349–360.
Google Scholar | Crossref | Medline47. Wang, Y, Gao, X, Zhang, X, et al. Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease. Gut Microbes 2021; 13: 1–18.
Google Scholar | Crossref48. Bjerrum, JT, Steenholdt, C, Ainsworth, M, et al. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. BMC Med 2017; 15: 184.
Google Scholar | Crossref | Medline49. Lichtenstein, GR, Loftus, EV, Isaacs, KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 2018; 113: 481–517.
Google Scholar | Crossref | Medline50. Rubin, DT, Ananthakrishnan, AN, Siegel, CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019; 114: 384–413.
Google Scholar